KEYTRUDA®

Therapeutic Area: Oncology

Drug Type: Biologic

Molecule: Pembrolizumab

Clinical Phase: Approved

Pipeline Status: Active

Indication: The Keytruda (pembrolizumab) oncology indications have expanded significantly, now encompassing over 38 distinct regulatory approvals across a diverse spectrum of solid tumors and hematologic malignancies. Its foundational role in modern cancer care is most prominent in non-small cell lung cancer (NSCLC), where it is utilized as both a first-line monotherapy and in combination with chemotherapy for metastatic disease. Beyond respiratory tract cancers, it is a primary therapeutic option for advanced melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma. Notably, it remains a pioneer in precision medicine as the first immunotherapy to receive a "tissue-agnostic" approval for any advanced solid tumor exhibiting high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). As of 2026, the clinical landscape has shifted toward earlier intervention, with Keytruda pembrolizumab oncology applications now standard in neoadjuvant and adjuvant regimens for triple-negative breast cancer, muscle-invasive bladder cancer, and resectable NSCLC. This extensive therapeutic reach is further supported by the introduction of subcutaneous administration for many of these indications, ensuring that pembrolizumab remains the versatile, global backbone of multi-modal oncological treatment strategies.

Mechanism of Action: Keytruda (pembrolizumab) functions as a high-affinity, humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, a critical immune checkpoint found on T-lymphocytes. In a healthy state, the PD-1 pathway serves to prevent overactive immune responses; however, many malignant tumors exploit this system by expressing ligands PD-L1 and PD-L2, which bind to the PD-1 receptor and effectively "turn off" the T-cell’s ability to attack the cancer. By binding to the PD-1 receptor itself, pembrolizumab physically blocks the interaction with these inhibitory ligands, thereby releasing the "molecular brakes" on the immune system. This reactivation allows the patient's own cytotoxic T-cells to recognize, infiltrate, and destroy tumor cells across a vast range of histological origins. The 2026 introduction of Keytruda Qlex further optimizes this mechanism by utilizing berahyaluronidase alfa to increase tissue permeability, allowing the pembrolizumab molecule to reach systemic circulation rapidly via subcutaneous injection without compromising its binding efficacy or therapeutic potency.